32 days to first decision for reviewed manuscripts only
21 days to first decision for all manuscripts
59 days from submission to acceptance
12 days from acceptance to publication
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated morbidity and mortality for children and adults. Developing novel and effective molecular-targeted...
Citation: Experimental Hematology & Oncology 2017 6:10